Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUS-TIMI 54

AIMS: In PEGASUS-TIMI 54, ticagrelor significantly reduced the risk of the composite of major adverse cardiovascular (CV) events by 15–16% in stable patients with a prior myocardial infarction (MI) 1–3 years earlier. We report the efficacy and safety in the subpopulation recommended for treatment in...

Descripción completa

Detalles Bibliográficos
Autores principales: Dellborg, Mikael, Bonaca, Marc P, Storey, Robert F, Steg, P Gabriel, Im, Kyung A, Cohen, Marc, Bhatt, Deepak L, Oude Ophuis, Ton, Budaj, Andrezej, Hamm, Christian, Spinar, Jindrich, Kiss, Robert G, Lopez-Sendon, José, Kamensky, Gabriel, Van de Werf, Frans, Ardissino, Diego, Kontny, Frederic, Montalescot, Gilles, Johanson, Per, Bengtsson, Olof, Himmelmann, Anders, Braunwald, Eugene, Sabatine, Marc S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6749839/
https://www.ncbi.nlm.nih.gov/pubmed/31218354
http://dx.doi.org/10.1093/ehjcvp/pvz020

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6749839/
https://www.ncbi.nlm.nih.gov/pubmed/31218354
http://dx.doi.org/10.1093/ehjcvp/pvz020

Ejemplares similares